PRP biology is shaped by platelet dose, cellular composition, and preparation technique. Explore how the cells ultimately delivered to the treatment site influence the biological conversation that follows.
PRP should not be defined by platelet concentration alone. Leukocyte composition, activation state, tissue context, dose, and processing technique can all influence the biological environment. The pathways below illustrate important differences in cellular signaling, but they should be viewed as biological models rather than fixed clinical outcomes.
PRP is commonly classified as leukocyte-rich PRP (LR-PRP) or leukocyte-poor PRP (LP-PRP), but total white blood cell concentration does not fully describe the cellular composition of a PRP preparation. Monocytes and neutrophils perform different biological functions, and two preparations with similar total leukocyte counts may contain very different leukocyte populations.
This distinction may be important because PRP is not simply a platelet concentrate. It is a cellular and molecular preparation in which platelets, leukocyte subpopulations, plasma proteins, cytokines, and other signaling molecules can interact with the local tissue environment. Understanding which cells are present may therefore provide more biological information than labeling a preparation simply "leukocyte-rich" or "leukocyte-poor."
Monocytes are precursors to macrophages and participate in inflammatory regulation, angiogenesis, debris clearance, extracellular-matrix remodeling, and tissue repair. Macrophages are highly plastic cells whose functional phenotype can change throughout the healing response. This provides a biological rationale for considering mononuclear-cell composition separately from total leukocyte concentration when characterizing PRP.
A review by Lana and colleagues specifically examined the potential role of monocytes and macrophages in PRP and proposed that macrophage plasticity and the transition from inflammatory toward resolving functions may contribute to PRP-mediated tissue repair. Lana et al., 2019
In an experimental study using human monocyte-derived macrophages, Uchiyama and colleagues found that PRP preparations suppressed several markers associated with M1 macrophage polarization and increased markers associated with M2-like polarization. Both leukocyte-poor PRP and a leukocyte-containing autologous protein solution influenced macrophage phenotype, with differences observed between the preparations for several measured markers. These findings support biological interaction between PRP-derived signaling factors and macrophages, although macrophage behavior in vivo is more complex than a simple M1/M2 model. Uchiyama et al., 2021
Neutrophils are essential components of innate immunity and early tissue repair, but they also provide a different inflammatory and proteolytic environment than mononuclear cells. Neutrophil-rich preparations can contribute reactive oxygen species, inflammatory mediators, proteases, and neutrophil extracellular trap-associated signaling. These responses are not inherently beneficial or detrimental. Their effects depend on concentration, timing, tissue, indication, and the local disease environment. The distinction reinforces why total leukocyte count alone may be an incomplete description of PRP cellular composition.
Clinical evidence has not established that one leukocyte formulation is universally superior. A 2026 systematic review and network meta-analysis included 21 randomized controlled trials and 2,254 patients with knee osteoarthritis. Both leukocyte-rich PRP and leukocyte-poor PRP produced significant functional improvement compared with placebo, while direct comparison did not demonstrate a statistically significant difference in efficacy between LR-PRP and LP-PRP. Xu et al., 2026
A separate 2026 systematic review examining leukocyte-rich versus leukocyte-poor PRP for osteoarthritis similarly concluded that current evidence is insufficient to determine whether the inclusion of leukocytes provides a consistent clinical advantage. Together, these findings argue against treating the labels LR-PRP and LP-PRP as complete descriptions of the biological preparation. 2026 systematic review
The separation device, centrifugation stability, draw-volume capacity, recovery efficiency, and collection method all influence which cells reach the final preparation.
Current evidence increasingly supports evaluating PRP by the absolute number of platelets delivered, rather than concentration factor alone. In knee osteoarthritis, recent systematic reviews have identified an association between platelet dose and clinical outcomes. A 2026 systematic review and meta-analysis found that PRP preparations delivering 5 to 10 billion platelets were associated with the largest functional effect size compared with hyaluronic acid. The optimal platelet dose remains indication-specific and has not been established across all musculoskeletal conditions. Hooper et al., 2026
A PRP preparation can have a high platelet concentration but still deliver a modest total platelet dose if the final injectable volume is small. Absolute platelet dose describes the total number of platelets delivered to the treatment site.
Platelet dose-response evidence is currently strongest in knee osteoarthritis. In a 2026 meta-analysis of 32 randomized trials, investigators categorized PRP as 1 to 5 billion, 5 to 10 billion, or greater than 10 billion total deliverable platelets. All three groups demonstrated clinical improvement, while the 5 to 10 billion group showed the largest functional effect size compared with hyaluronic acid. Hooper et al., 2026
A separate systematic review found that knee osteoarthritis studies reporting significant positive outcomes delivered an average platelet dose of approximately 5.5 billion, compared with approximately 2.3 billion in studies without a significant positive difference. These findings support evaluating total deliverable platelet dose, but they do not establish a universal therapeutic dose for PRP. Berrigan et al., 2025
Blood-draw volume may provide another useful window into platelet dose when the final PRP platelet count is not reported. In a 2026 systematic review and meta-analysis of 62 randomized trials involving 4,969 patients with knee osteoarthritis, Centeno and colleagues evaluated total blood-draw volume as a proxy for the platelet inventory available for PRP preparation. Among trials comparing PRP with hyaluronic acid, preparations using ≥40 mL of blood were associated with larger improvements in 6-month WOMAC and 12-month VAS outcomes than preparations using <40 mL. Centeno et al., 2026
Platelet dose is the total number of platelets contained in the final PRP volume delivered to the patient. When the platelet concentration of the final PRP is known, total platelet dose can be calculated directly.
When planning a PRP preparation before processing, the potential platelet dose also depends on the patient's baseline platelet count, the actual volume of whole blood collected, and the percentage of available platelets recovered by the preparation system.
Concentration describes how densely platelets are suspended in the final PRP. Dose describes how many total platelets are actually delivered. A higher concentration therefore does not automatically produce a higher platelet dose.
Use the patient's baseline platelet count, intended blood draw, and expected system recovery to model the platelet dose available for treatment.
Open the PRPdose Calculator →Platelet dose tells us how many platelets are delivered. It does not tell us the biological age, functional state, molecular cargo, or responsiveness of every platelet within that dose.
Circulating platelets are a heterogeneous population. At any given time, a patient's blood contains newly released immature platelets as well as platelets that have already spent several days in circulation. Both populations are counted equally by a standard platelet count, even though their molecular and functional characteristics may differ.
Immature platelets, sometimes called reticulated platelets, retain greater amounts of residual RNA and represent the youngest platelets released into circulation. The proportion of these cells can be estimated using the immature platelet fraction, or IPF. Mean platelet volume, or MPV, may provide additional information about platelet populations, but platelet size should not be treated as a direct or interchangeable measure of platelet age. Handtke & Thiele, 2020
Two PRP preparations may contain the same total platelet dose while differing in the biological characteristics of the platelets within that dose.
Human platelets circulate for approximately 7 to 10 days. Because platelets are continuously produced and cleared, a blood sample contains platelets at different stages of their circulating lifespan. Platelet aging is accompanied by measurable changes in protein content, mitochondria, signaling, structure, and function. Machlus et al., 2024
Immature platelets generally contain more residual RNA and demonstrate characteristics associated with greater biosynthetic and functional activity. As platelets age in circulation, their proteome and cellular machinery progressively change. Importantly, this should not be interpreted as simple spontaneous degranulation. Rather, aging appears to alter both the platelet's remaining molecular inventory and its ability to respond when stimulation occurs.
Allan and colleagues separated platelets from healthy human donors according to thiazole-orange fluorescence as a surrogate marker of platelet RNA content and biological age. Proteomic, imaging, and functional testing demonstrated substantial differences between younger and older platelet populations. Allan et al., 2021
Uchino and colleagues evaluated blood-cell characteristics, including the immature platelet fraction, in 144 patients with knee osteoarthritis who received a single PRP injection. The investigators measured cellular characteristics in both peripheral blood and the resulting PRP and compared them with pain and functional outcomes. Uchino et al., 2021
Higher immature platelet fraction in peripheral blood was positively correlated with improvement in VAS pain and KOOS pain scores. In multivariable analysis, a higher whole-blood IPF% remained significantly associated with VAS improvement. IPF% within the PRP itself also showed a tendency toward correlation with pain improvement.
Interestingly, baseline whole-blood platelet concentration itself did not behave as a simple marker of better response. The study also found that a lower neutrophil percentage in the PRP was associated with improvements in VAS and KOOS activities of daily living. These findings suggest that PRP response may depend on biological characteristics of the patient's blood and final preparation, not simply platelet concentration alone. View full study
A 2025 review focused specifically on platelet aging and functional quality in regenerative medicine proposed that platelet senescence may represent an underrecognized source of PRP variability. The authors highlighted reduced granule content, impaired responsiveness, mitochondrial dysfunction, oxidative stress, and altered inflammatory behavior as potential consequences of platelet aging. Costa et al., 2025
This remains an emerging area rather than an established clinical dosing standard. At present, platelet biological age is best viewed as a potential quality variable that may help explain why preparations with similar platelet counts do not necessarily behave identically.
We know that circulating platelets differ in biological age, immature platelet fraction can be measured, platelet function changes with aging, and one clinical PRP study has associated higher IPF with greater short-term pain improvement in knee osteoarthritis.
We do not yet know the optimal immature platelet fraction for PRP, whether selectively enriching immature platelets improves clinical outcomes, whether different PRP systems reproducibly recover different platelet-age populations, or whether platelet quality should eventually modify a target platelet dose.
A PRP system does not begin with a standardized biological input. Every preparation starts with an individual patient's circulating platelet count and the amount of whole blood collected.
Patients can arrive with substantially different circulating platelet counts. If the same blood volume is collected from every patient, the number of platelets entering the PRP preparation can therefore vary dramatically before processing even begins.
The centrifuge cannot manufacture additional platelets. It can only separate and recover some percentage of the platelet inventory that was collected from the patient.
Platelet concentration can increase during processing because platelets are transferred into a smaller final plasma volume. But concentration does not create new platelets.
The examples below isolate baseline platelet count so the effect is easy to see. They represent whole-blood platelet inventory before anticoagulant dilution, sampling, transfer, or processing losses.
Processing efficiency determines how much of the starting platelet inventory ultimately reaches the PRP fraction. Using the middle example above, a patient with 250 M/µL and a 30 mL blood draw begins with approximately 7.5 billion platelets.
A 2023 study evaluated 403 PRP injections from 357 patients and examined how patient characteristics and baseline blood counts influenced final PRP composition. Baseline platelet count and patient age significantly influenced the final PRP platelet concentration. Rossi et al., 2023
Among patients who underwent PRP preparation twice, the investigators found a significant difference between the platelet concentration of the first and second preparations. This suggests that a previous PRP result should not automatically be assumed to represent the patient's platelet inventory or final preparation at a later treatment.
In a 2026 systematic review and meta-analysis of 62 randomized trials involving 4,969 patients with knee osteoarthritis, Centeno and colleagues examined total blood-draw volume as a proxy for platelet dose. Among trials comparing PRP with hyaluronic acid, blood draws of 40 mL or greater were associated with larger improvements in 6-month WOMAC and 12-month VAS outcomes than draws below 40 mL. Centeno et al., 2026
Blood-draw volume should not be interpreted as platelet dose itself. Baseline platelet count, anticoagulant volume, processing recovery, platelet losses, and final preparation determine how many platelets are ultimately delivered. The study nevertheless reinforces the relationship between the amount of blood collected and the platelet inventory available for PRP preparation.
Baseline platelet count, desired dose, and estimated processing recovery can be used to calculate the approximate blood volume needed rather than assuming the same collection volume is appropriate for every patient.
Model the Patient’s Platelet Dose →Centrifugation separates blood according to physical properties such as density, size, shape, relative centrifugal force, spin duration, tube geometry, and deceleration. The result is not simply plasma above one discrete buffy-coat line. It is a cellular gradient in which neighboring regions can contain very different proportions of platelets, mononuclear cells, granulocytes, and red blood cells.
There is no validated universal rule stating that exactly 0.1 millimeter of movement produces a specific change in PRP composition. The dimensions of the cellular interface vary with hematocrit, platelet count, tube geometry, centrifugal conditions, braking, and the individual preparation system.
The important principle is that once an aspiration tip approaches the interface, a very small change in collection position can move the tip from a predominantly platelet-containing region toward increasing mononuclear-cell, granulocyte, and eventually red-cell exposure.
Remaining higher in the plasma can reduce leukocyte and red-cell exposure, but collecting too conservatively may leave platelets near the interface behind.
Moving toward or through the buffy coat can increase platelet recovery, but it can also increase recovery of neighboring leukocyte populations and, with deeper collection, erythrocytes. The desirable balance depends on the cellular composition being targeted.
Centrifugation creates the separation pattern, but the collection method determines which part of that pattern becomes the final injectate.
In a manually aspirated system, small differences in needle or pipette position may therefore become differences in the cellular composition of the PRP. In automated systems, the same question shifts to sensor accuracy, valve timing, collection boundaries, and reproducibility.
Human buffy-coat separation studies have demonstrated sequential regions containing platelets, lymphocytes and monocytes, granulocytes, and erythrocytes. This supports viewing the interface as a structured gradient rather than one homogeneous white layer. Sutton et al., 1988
Density-separation experiments also demonstrate that mononuclear cells and granulocytes occupy different density ranges. This is one reason small changes in collection depth near the interface can alter leukocyte composition. Ito & Shinomiya, 2001
In a controlled laboratory study using 30 adult dogs and an ACP double-syringe PRP system, investigators compared PRP aspirated before entering the buffy coat with PRP collected after the buffy coat was pierced. Entering the buffy coat increased platelet concentration, but it also significantly increased leukocyte concentration and hematocrit. Although this was a veterinary study using a specific preparation system, it provides direct experimental evidence that aspiration technique can materially alter the cellular composition of the final PRP. Jones et al., 2024
If biologically different cell populations occupy neighboring regions, reproducibility depends on more than RPM and spin time. The design must also control how the interface is formed, identified, accessed, and collected.
Review recovery efficiency, aspiration method, cellular selectivity, RBC exclusion, centrifuge performance, and operator repeatability.
Review the PRP System Audit →Regenerative signaling does not end when inflammation decreases. Successful repair requires a coordinated transition from inflammation through proliferation and remodeling toward a tissue-specific extracellular matrix. The desired endpoint is different for tendon, ligament, cartilage, bone, and other tissues.
Tissue repair is dynamic. Early inflammatory signaling participates in debris clearance and initiation of repair. That response must then transition toward resolution, matrix deposition, organization, and maturation.
Platelet activation, neutrophils, inflammatory macrophage activity, cytokine release, debris clearance, and recruitment of additional repair cells.
Inflammatory signaling begins to resolve while macrophages, fibroblasts, tenocytes, progenitor cells, and vascular responses participate in new tissue formation.
Provisional matrix is reorganized. Collagen composition, orientation, cross-linking, extracellular-matrix turnover, and mechanical loading influence tissue maturation.
The biological goal is not simply more matrix. It is matrix with the composition, architecture, and mechanical behavior appropriate for the tissue being repaired.
Macrophages participate throughout tendon healing. Early inflammatory phenotypes contribute to phagocytosis and debris clearance, while later resolving phenotypes are associated with inflammation resolution, angiogenesis, extracellular-matrix deposition, and remodeling. Chisari et al., 2020
The biology is more complex than a simple M1-versus-M2 switch. Macrophage phenotypes exist along a functional spectrum, and their effects depend on timing, tissue environment, and the surrounding signaling network.
The biological endpoint depends on the composition, organization, and mechanical properties of the extracellular matrix that ultimately forms. Tendon and ligament repair progressively remodels toward an increasingly aligned, Type I collagen-dominant architecture. Articular cartilage presents a different target: a Type II collagen- and proteoglycan-rich hyaline-like matrix rather than Type I-dominant fibrocartilaginous repair.
Conceptual illustrations of tissue-specific extracellular-matrix remodeling. These pathways represent biological principles rather than fixed clinical timelines. Healing varies with tissue type, injury severity, patient biology, mechanical environment, rehabilitation, and treatment.
Tendons and ligaments are predominantly composed of Type I collagen. Following injury, early repair produces a relatively disorganized matrix with increased Type III collagen. During remodeling, the collagen matrix becomes increasingly organized and Type I collagen again becomes more prominent. Molecular and Biologic Effects of PRP in Ligament and Tendon Healing, 2023
Experimental PRP literature suggests that platelet-derived signaling can influence tenocyte activity, cellular proliferation, matrix production, vascular responses, and collagen remodeling. Results remain heterogeneous, however, and differences in PRP composition, dose, preparation method, injury model, and rehabilitation make universal conclusions difficult.
Native articular cartilage derives much of its mechanical behavior from a specialized extracellular matrix containing predominantly Type II collagen and a high concentration of proteoglycans. The structure of that matrix is central to cartilage's ability to resist compression and provide a durable, low-friction articulating surface. Pueyo Moliner et al., 2025
Repair after chondral injury can instead produce fibrocartilaginous tissue with greater Type I collagen representation and matrix architecture that differs from normal hyaline articular cartilage. The presence of repair tissue therefore does not necessarily mean that native cartilage structure has been restored. Martínez-Moreno et al., 2021
PRP does not directly manufacture tendon or cartilage. It introduces platelets, soluble mediators, and, depending on the preparation, leukocyte populations into an existing biological environment. Those signals interact with resident cells, recruited immune cells, extracellular matrix, mechanical loading, disease state, and the patient's own healing response.
This is one reason a single universal PRP composition may not be optimal for every indication or every phase of repair. The biological question is not simply how much inflammatory or regenerative signaling is present. It is whether that signaling environment is appropriate for the tissue and biological state in which it is delivered.
PRP is not defined by platelet concentration alone. Patient platelet inventory, processing recovery, absolute platelet dose, platelet quality, cellular composition, collection technique, and the tissue environment all contribute to the biological preparation ultimately delivered.
Use the patient's baseline platelet count, blood-draw volume, processing recovery, and final preparation to estimate the total platelet dose available for treatment.
Open PRPdose Calculator →Examine platelet recovery, RBC exclusion, cellular selectivity, aspiration method, centrifuge performance, draw-volume capability, and operator-to-operator repeatability.
Open the PRP System Audit →